Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Assistenzarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
2023 WS
-
2023 SS
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC) Jg. 200 (2024) 113536Online Volltext: dx.doi.org/ (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology Jg. 15 (2024) 1383125Online Volltext: dx.doi.org/ (Open Access)
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC) Jg. 208 (2024) 114208Online Volltext: dx.doi.org/ (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC) Jg. 183 (2023) S. 1 - 10Online Volltext: dx.doi.org/
-
Database for queries of melanoma cohorts with molecular and clinical dataIn: Pigment Cell and Melanoma Research Jg. 36 (2023) Nr. 2, S. 252 - 258Online Volltext: dx.doi.org/ (Open Access)
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research Jg. 29 (2023) Nr. 15, S. 2894 - 2907Online Volltext: dx.doi.org/
-
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma : a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) Jg. 188 (2023) S. 140 - 151Online Volltext: dx.doi.org/
-
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 - 77Online Volltext: dx.doi.org/ (Open Access) -
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21Online Volltext: dx.doi.org/ (Open Access) -
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
ESMO Congress 2023 ; 20 - 24 October 2023 Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S694Online Volltext: dx.doi.org/ -
TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entitiesIn: PLoS ONE Jg. 18 (2023) Nr. 7, e0281487Online Volltext: dx.doi.org/ (Open Access)
-
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
Joint Conference of the Société Française d'Immunologie (SFI) and the Deutsche Gesellschaft für Immunologie (DGfI) ; 26 - 29 September, 2023, Strasbourg, France,In: European Journal of Immunology Jg. 53 (2023) Nr. S2, Special issue: Abstracts: Joint Conference of the Société Française d'Immunologie (SFI) and the Deutsche Gesellschaft für Immunologie (DGfI), 26–29 September, 2023, Strasbourg, France, S. 152Online Volltext: dx.doi.org/ (Open Access) -
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesIn: Immunity Jg. 56 (2023) Nr. 6, S. 1341 - 1358.e11Online Volltext: dx.doi.org/ (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research Jg. 35 (2022) Nr. 6, S. 573 - 586Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 7,Online Volltext: dx.doi.org/ (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers Jg. 14 (2022) Nr. 9, 2090Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers Jg. 14 (2022) Nr. 17, 4066Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 84Online Volltext: dx.doi.org/ -
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer Jg. 151 (2022) Nr. 9, S. 1542 - 1554Online Volltext: dx.doi.org/ (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC) Jg. 166 (2022) S. 60 - 72Online Volltext: dx.doi.org/
-
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 6Online Volltext: dx.doi.org/ -
MAPKinase Inhibition nach Versagen einer PD-1 basierten Immuncheckpoint Blockade in Patienten:innen mit fortgeschrittenem Melanom : eine Auswertung des multizentrischen prospektiven Hautkrebsregisters ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 28Online Volltext: dx.doi.org/ -
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma : An evaluation of the multicenter prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) Jg. 167 (2022) S. 32 - 41Online Volltext: dx.doi.org/ (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging Jg. 22 (2022) Nr. 1,Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 88Online Volltext: dx.doi.org/ -
Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S915 - S916Online Volltext: dx.doi.org/ (Open Access) -
Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC)
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S924 - S925Online Volltext: dx.doi.org/ (Open Access) -
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 16 - 17Online Volltext: dx.doi.org/ -
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma : An international, retrospective, cohort studyIn: Annals of Oncology Jg. 33 (2022) Nr. 9, S. 968 - 980Online Volltext: dx.doi.org/
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC) Jg. 161 (2022) S. 99 - 107Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS) Jg. 23 (2022) Nr. 6, 3324Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 75 - 76
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) Jg. 152 (2021) S. 139 - 154Online Volltext: dx.doi.org/
-
Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 876 - S.877Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
48th Annual Scientific Meeting Cancer care and research: Learning from the past and improving the future, 16-18 November 2021,In: Asia-Pacific Journal of Clinical Oncology Jg. 17 (2021) Nr. 9, SI, S. 64 - 65Online Volltext: dx.doi.org/ (Open Access) -
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsIn: Frontiers in Genetics Jg. 12 (2021) 663272Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology Jg. 11 (2021) 765608Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) Jg. 147 (2021) S. 170 - 181Online Volltext: dx.doi.org/
-
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 59 - 60
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 395 - 404Online Volltext: dx.doi.org/
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 340 - 347Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) Jg. 159 (2021) S. 113 - 124Online Volltext: dx.doi.org/ (Open Access)
-
Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular TumorsIn: Dermato Jg. 1 (2021) Nr. 1, S. 18 - 25Online Volltext: dx.doi.org/ (Open Access)
-
Response to comment : Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC) Jg. 157 (2021) S. 514 - 515Online Volltext: dx.doi.org/
-
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 37 - 48Online Volltext: dx.doi.org/ (Open Access)
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 31
-
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsIn: European Journal of Cancer (EJC) Jg. 155 (2021) S. 268 - 280Online Volltext: dx.doi.org/
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology Jg. 10 (2020) S. 592609Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 10, S. 1165 - 1168Online Volltext: dx.doi.org/ (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD Jg. 183 (2020) Nr. 5, S. 928 - 939Online Volltext: dx.doi.org/ (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist Jg. 61 (2020) Nr. 7, S. 669 - 675Online Volltext: dx.doi.org/ (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 8, S. 713 - 720Online Volltext: dx.doi.org/
-
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer (EJC) Jg. 111 (2019) S. 148 - 154Online Volltext: dx.doi.org/ (Open Access)
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 66 - 76Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer (EJC) Jg. 113 (2019) S. 47 - 54Online Volltext: dx.doi.org/ (Open Access)
-
Extramammärer Morbus PagetIn: Der Hautarzt Jg. 70 (2019) Nr. 9, S. 670 - 676Online Volltext: dx.doi.org/
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 141Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Pruritus in patients with chronic leg ulcers : a frequent and often neglected problemIn: International Wound Journal (IWJ) Jg. 16 (2019) Nr. 6, S. 1464 - 1470Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 61 - 62Online Volltext: dx.doi.org/ (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 26 - 27Online Volltext: dx.doi.org/ (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 3
-
Evolution of cross‐resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. 6, S. 53Online Volltext: dx.doi.org/ (Open Access) -
Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatmentIn: OncoImmunology Jg. 7 (2018) Nr. 8, e1450127Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 3Online Volltext: dx.doi.org/ (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 38Online Volltext: dx.doi.org/ (Open Access) -
Characterization of Vemurafenib- and IFNy-induces senescence-like melanoma phenotypes and their influence on NK and T cell sensitivity of tumor cellsDuisburg ; Essen (2017) 94 Blätter
-
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. Suppl. 3, S. 26 - 27Online Volltext: dx.doi.org/